Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2013 Sep;45(3):193-201. doi: 10.4143/crt.2013.45.3.193. Epub 2013 Sep 30.
The purpose of this study was to determine whether chemoradiation (CCR) is efficient for improving prognosis, compared with systemic chemotherapy (SC), in patients with stage IVB cervical cancer who have distant lymphatic metastasis.
Among 2,322 patients with cervical cancer between January 2000 and March 2010, 43 patients (1.9%) had stage IVB disease. After exclusion of 19 patients due to insufficient data and hematogenous metastasis, 24 patients (1%) who received CCR (n=10) or SC (n=14) were enrolled. We compared tumor response, progression-free survival (PFS) and overall survival (OS), and disease recurrence between CCR and SC.
Complete response rates were 60% and 0% after CCR and SC (p<0.01). Grade 3 or 4 leukopenia was more common in patients treated with CCR (24.4% vs. 9.1%, p=0.03), whereas grade 3 or 4 neuropenia was more frequent in those treated with SC (28.4% vs. 11.1%, p=0.03). Development of grade 3 proctitis occurred as a late radiotherapy (RT)-related toxicity in only one patient (10%) treated with CCR. In addition, squamous cell carcinoma and CCR were favorable prognostic factors for improvement of PFS (adjusted hazard ratios [HRs], 0.17 and 0.12; 95% confidence intervals [CIs], 0.04 to 0.80 and 0.03 to 0.61), and only CCR was significant for improvement of OS (adjusted HR, 0.15; 95% CI, 0.02 to 0.90). However, no differences in the rate and pattern of disease recurrence were observed between CCR and SC.
CCR may be more effective than SC for improving survival, and can be regarded as a feasible method with some caution regarding late RT-related toxicity for treatment of stage IVB cervical cancer with distant lymphatic metastasis.
本研究旨在确定对于存在远处淋巴结转移的 IVB 期宫颈癌患者,与全身化疗(SC)相比,化放疗(CCR)是否能改善预后。
在 2000 年 1 月至 2010 年 3 月期间,2322 例宫颈癌患者中,43 例(1.9%)为 IVB 期疾病。排除 19 例因数据不足和血行转移的患者后,入组了 24 例(1%)接受 CCR(n=10)或 SC(n=14)的患者。我们比较了 CCR 和 SC 之间的肿瘤反应、无进展生存期(PFS)和总生存期(OS)以及疾病复发率。
CCR 治疗后的完全缓解率为 60%,SC 治疗后的完全缓解率为 0%(p<0.01)。CCR 治疗组白细胞减少症 3 或 4 级发生率较高(24.4%比 9.1%,p=0.03),而 SC 治疗组神经毒性 3 或 4 级发生率较高(28.4%比 11.1%,p=0.03)。只有 1 例(10%)接受 CCR 治疗的患者出现晚期放疗(RT)相关的 3 级直肠炎。此外,鳞状细胞癌和 CCR 是改善 PFS 的有利预后因素(调整后的危险比[HR],0.17 和 0.12;95%置信区间[CI],0.04 至 0.80 和 0.03 至 0.61),仅 CCR 对 OS 的改善有统计学意义(调整后的 HR,0.15;95%CI,0.02 至 0.90)。然而,在 CCR 和 SC 之间,疾病复发的发生率和模式没有差异。
与 SC 相比,CCR 可能更有效地改善生存,并且对于存在远处淋巴结转移的 IVB 期宫颈癌患者,在考虑晚期 RT 相关毒性的情况下,CCR 可以作为一种可行的治疗方法。